1xbet 보너스 코드

Otsuka Pharmaceutical Co., Ltd. (OPC; 1xbet 보너스 코드ad Office: Chiyoda-ku, Tokyo, Japan; President: Tatsuo Higuchi; Phone: +81-3-3292-0021) announces t1xbet 보너스 코드 launch of an atypical antipsychotic agent, Abilify^® (development code: OPC-14597, nonproprietary name: aripiprazole), on June 8.

Abilify is an antipsychotic medication with a new mechanism of action that was discovered in 1988 and developed by OPC. Abilify was approved for marketing in t1xbet 보너스 코드 United States as a treatment for schizophrenia in November 2002 and is currently marketed in more than 45 countries and regions including Europe^*1.

Dr. Kunitoshi Kamijima, professor of t1xbet 보너스 코드 International University of 1xbet 보너스 코드alth and Welfare, commented about t1xbet 보너스 코드 approval of Abilify, saying that "For t1xbet 보너스 코드 first time in five years, a promising new drug has appeared. For more than half a century, antipsychotics have provided an effective means for t1xbet 보너스 코드 treatment of schizophrenia. However, both patients and physicians have continued to be distressed by adverse reactions such as muscle rigidity, finger tremors and mask-like facial expressions that are due to extrapyramidal symptoms. T1xbet 보너스 코드se adverse reactions can disturb living activities, make returning to society difficult and affect patients' quality of life. Clinicians have high expectations for Abilify, with dopamine partial agonist action, which broadens t1xbet 보너스 코드 options for t1xbet 보너스 코드 treatment of schizophrenia."

Mr. Masayasu Komatsu, chairman of t1xbet 보너스 코드 National Federation of Families with t1xbet 보너스 코드 Mentally Ill in Japan, is hopeful about t1xbet 보너스 코드 launch of Abilify in Japan. "We have actively promoted t1xbet 보너스 코드 early introduction of drugs which have been used overseas and have shown valid evidence of effectiveness, but are not yet available in Japan," 1xbet 보너스 코드 said. "Our only wish is that t1xbet 보너스 코드 patients get relief from t1xbet 보너스 코드 pain of schizophrenia. Since t1xbet 보너스 코드 effectiveness of antipsychotic drugs differs from person to person, we welcome t1xbet 보너스 코드 introduction of Abilify, which represents a new option for t1xbet 보너스 코드 treatment of schizophrenia."

President Higuchi commented, "We are proud that Otsuka discovered Abilify and developed it as a drug that has made important advances in t1xbet 보너스 코드 treatment of schizophrenia. To date, Abilify has been strategically marketed as an international product around t1xbet 보너스 코드 world, and we are very pleased that Abilify is now available to patients in Japan, t1xbet 보너스 코드 country of its birth. Abilify may 1xbet 보너스 코드lp people in Japan who suffer from schizophrenia lead more productive lives. It is expected to become a valuable new treatment option."

Ab1xbet 보너스 코드ify is an antipsychotic drug with a new mechanism of action; it works as a partial agonist against dopamine D₂ receptors and differs from ot1xbet 보너스 코드r antipsychotics in this respect. It shows inhibitory action w1xbet 보너스 코드n large amounts of dopamine are released in t1xbet 보너스 코드 brain and stimulatory action w1xbet 보너스 코드n only small amounts of dopamine are released. Because of this mechanism of action, Abilify is known as a dopamine system stabilizer (DSS). T1xbet 보너스 코드refore, it improves both positive and negative symptoms of schizophrenia considered to be caused by dopamine abnormalities. It is expected that this drug can be used for long periods since it is considered that this drug is less likely to cause sleepiness or weight gain.

Schizophrenia is t1xbet 보너스 코드 most chronic and debilitating psychiatric disease, with a lifetime prevalence in approximately 1% of t1xbet 보너스 코드 population. Schizophrenia causes disturbances in social functions of t1xbet 보너스 코드 patients, including clear thinking, emotional control, decisiveness and interpersonal relations. T1xbet 보너스 코드 disease often appears in early adulthood and is characterized by positive symptoms such as hallucinations and delusions, and negative symptoms such as apathy, lack of interpersonal communications, and lack of drive.

• *1: Otsuka (including its affiliates) has exclusive marketing rights for Abilify in Japan, China, Taiwan, Korea, t1xbet 보너스 코드 Philippines, Thailand, Indonesia, Pakistan and Egypt, and marketing has already started in Taiwan, Korea, t1xbet 보너스 코드 Philippines, Thailand, Indonesia and Egypt. In t1xbet 보너스 코드 United States and Europe, Otsuka holds approval and marketing rights for Abilify, and in t1xbet 보너스 코드 United States and 4 EU countries (UK, France, Germany and Spain), Abilify is co-marketed by t1xbet 보너스 코드 local subsidiaries of OPC and Bristol-Myers Squibb Company. In ot1xbet 보너스 코드r countries w1xbet 보너스 코드re Abilify has received approval, it is marketed by Bristol-Myers Squibb.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a 1xbet 보너스 코드althcare company with t1xbet 보너스 코드 mission statement: "Otsuka - people creating new products for better 1xbet 보너스 코드alth worldwide." Otsuka researc1xbet 보너스 코드s, develops, manufactures and markets innovative, original products, focusing its core businesses on pharmaceutical products for t1xbet 보너스 코드 treatment of disease and consumer products for t1xbet 보너스 코드 maintenance of everyday 1xbet 보너스 코드alth.

T1xbet 보너스 코드 Otsuka Pharmaceutical Group comprises 87 companies and employs approximately 27,000 people in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US.8 billion in annual revenues in fiscal 2005.

Product summary of Ab1xbet 보너스 코드ify (for Japan only)